NXN
NEXSEN LTD FPO [NXN]
Healthcare · ASX Small Cap
$0.1900 +15.2%
Updated 26 Mar 2026 · Scores refresh every scan
Score Breakdown
Technical75
Catalyst53
Sentiment50
Fundamental72
Momentum44
Risk Gate42
Get alerts when NXN's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- MACD momentum is picking up steam
- Pressing against the upper Bollinger Band — extended and may need to cool off
- Volume surging at 3.0x normal while price climbs — real buying conviction behind this move
- Knocking on the door of resistance — if it punches through, things could get interesting
- On a tear — up 18.8% over the last 5 days
- Beating the Small Ords index — relative strength of 1.18, so it's outpacing the pack
- Volatility is expanding fast — choppy price action, so buckle up
- Adequate cash runway (8 quarters)
- Small-cap ($20-100M)
- CANSLIM S: Tight float (35%)
- CANSLIM I: Institutional ownership (36%)
- Sentiment is mixed — no strong consensus either way
- The bigger volume days are the up days — volume-weighted momentum is positive (2.33%/day)
- Altman Z-Score distress zone (1.73 < 1.81, low-confidence approx)
- RBA hiking (-3pts)
Risk Signals
- Piotroski F-Score weak (3/9, low-confidence approx)
- Not enough chatter to gauge sentiment — defaulting to neutral
- Long-term momentum is negative — down 36% over the past year
- Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about NXN
3 free messages/day · Unlimited with Pro
Recent Catalysts
NONE Nexsen accelerates global rollout for StrepSure
NONE FDA feedback derisks US approval pathway for StrepSure
NONE Half Yearly Report and Accounts
Announcement tone +3pts
Recent ASX Announcements
| 2026-03-25 | Nexsen accelerates global rollout for StrepSure PRICE SENSITIVE |
| 2026-03-22 | FDA feedback derisks US approval pathway for StrepSure PRICE SENSITIVE |
| 2026-02-26 | Half Yearly Report and Accounts PRICE SENSITIVE |
| 2026-02-26 | Change in substantial holding - Nexsen |
| 2026-02-24 | Nexsen highlights GBS strategy at ISSAD 2026 |
Key Metrics
$34.0M
Market Cap
361K
Avg Volume
3.0x
Vol Ratio
$0.13 — $0.32
52-Week Range
N/A
Short Interest
N/A
Cash Runway
N/A
ROE
N/A
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | insufficient_data | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | pass | Float: 35% |
| L | Leader vs Laggard | pass | RS: 4 |
| I | Institutional Sponsorship | pass | Inst: 36% |
| M | Market Direction | neutral | Neutral |
Sector: Healthcare
Ranked #41 of 117 · Sector avg: 46
View all Healthcare signals →Track NXN and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.
No credit card required